Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity
about
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesRapid optimization and prototyping for therapeutic antibody-like molecules.Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activityA stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activityHER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsFab-based bispecific antibody formats with robust biophysical properties and biological activityRearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokineticsEngineering the variable region of therapeutic IgG antibodies.Emerging antibody combinations in oncology.Dual targeting strategies with bispecific antibodies.New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression systemNovel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments.Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies.The making of bispecific antibodies6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.Rational engineering of antibody therapeutics targeting multiple oncogene pathways.
P2860
Q33846405-86C76E9A-C6A9-4081-8EE9-EB360E3D19BEQ34406479-2862B319-13D3-4308-AA36-FBEBC87AA2C9Q34580658-A117B692-4A9B-43EC-A3B0-49385B89CA84Q34601167-CDC5B5A9-3940-491B-8492-1BC3228A0033Q35146077-0EAD46DD-6D3B-43ED-8A04-885DB8AD6A02Q35201923-ABAFCFE3-0E71-443B-80B2-1CC48EA27F57Q36213193-7C61A595-7F33-42E0-9835-E66863A775ADQ36216009-463D93C4-C958-4C9E-AAF7-3512657404FAQ37853324-121A2E6D-51FE-47A1-B62E-DCC20A454A5FQ37893414-43E2F4A8-F2A6-4870-A2C1-0C0FAD652B32Q37997559-742B0673-D113-4983-9B97-102CAE3DA12EQ38289992-C96BB47C-BBD3-4A8E-BD70-B89C54E6F05FQ41647084-F721428B-7011-4D29-B674-79B44579988CQ41837643-3961B65F-110D-4AD8-AAFC-CB17D05B7908Q41838529-08CED053-1F52-40A6-89CE-EC376676F4B8Q42323236-4058F7A5-9158-4FB3-A5AB-5C37DBC5F87CQ42732008-8EC79783-01EB-4D5C-9D61-FD86DAE03E07Q42854245-34E61E12-3479-42A7-98A9-A17BD7159748
P2860
Stable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@ast
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@en
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@nl
type
label
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@ast
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@en
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@nl
prefLabel
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@ast
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@en
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@nl
P2093
P2860
P356
P1476
Stable IgG-like bispecific ant ...... ockade and anti-tumor activity
@en
P2093
Adam Doern
Alexey Lugovskoy
Antonio Boccia
Arlene Sereno
Brian R Miller
Emma Langley
Flora Huang
Gisela Chiang
Heather Gouvis
P2860
P304
P356
10.1074/JBC.M110.184317
P407
P577
2010-12-01T00:00:00Z